Ana M Giménez-Arnau

Prof. Dr. Ana M Giménez-Arnau


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
AGAna M Giménez-Arnau
Ana M Giménez-Arnau
GDG. Deza
G. Deza
ABA. Bauer
A. Bauer
GJG.A. Johnston
G.A. Johnston
VMV. Mahler
V. Mahler
WUW. Uter
W. Uter

1 January 2015 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
KWKarsten Weller
Karsten Weller
MMMarcus Maurer
Marcus Maurer
CGClive Grattan
Clive Grattan
ANAlla Nakonechna
Alla Nakonechna
MAMohamed Abuzakouk
Mohamed Abuzakouk
MBMaria-Magdalena Balp
Maria-Magdalena Balp
Background: Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of licensed, recommended doses of modern, second‐generation H1‐antihistamines. So far, the humanistic, societal and economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost‐effective manner.Methods: ASSURE‐CSU is an observational, multicenter study being conducted in the UK, Germany, Canada, France, Italy, Spain, and The Netherlands. The study comprises a retrospective medical chart review in conjunction with patient surveys (including validated tools for assessment of disease impact) and an 8‐day patient diary. The primary objectives of the study are to describe patient demographics, medical history, treatments, and healthcare resource utilization based on medical‐record data and to assess the impact of disease, healthcare resource utilization, work days missed, and productivity loss based on patient‐reported data. Approximately 700 patients (aged ≥18 years) will be enrolled who have CSU/CIU despite currently receiving treatment, and have had persistent symptoms for at least 12 months. Data will be collected retrospectively for the 12 months (±1 month) prior to enrolment wherever possible, and prospectively for the week following enrolment.Discussion: ASSURE‐CSU will be the first study to examine the economic and humanistic burden of disease in patients diagnosed with CSU/CIU who are symptomatic despite treatment. By combining retrospective evaluation of medical records with prospective patient surveys and 8‐day diaries, across seven different countries, the ASSURE‐CSU study will contribute to a better understanding and acknowledgement of the burden of disease in patients with symptomatic chronic spontaneous urticaria.

2 February 2017 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
AGAna M Giménez-Arnau
Ana M Giménez-Arnau
Introduction: Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, phase II (X-CUISITE, MYSTIQUE), and pivotal phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL). Expert opinion: Omalizumab is a clinically effective and safe biological therapy for treating H1-antihistamine refractory CSU patients. It significantly reduces CSU symptoms (hives, itch and angioedema), and improves patient health-related quality of life. While omalizumab is already integral to the treatment of antihistamine refractory CSU, widespread use will depend on legal and economic factors, as well as improvements in the early and accurate diagnosis of CSU patients who would benefit from treatment.

16 April 2025 in The Lancet
Verified
Journal Article
Closed access
AGAna M Giménez-Arnau
Ana M Giménez-Arnau
APAndreas Pinter
Andreas Pinter
WSWiebke Sondermann
Wiebke Sondermann
ZRZiad Reguiai
Ziad Reguiai
RWRichard Woolf
Richard Woolf
ABAndrea Bauer
Andrea Bauer

18 August 2016 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
AGAna M Giménez-Arnau
Ana M Giménez-Arnau
SSSheldon Spector
Sheldon Spector
EAEvgeniya Antonova
Evgeniya Antonova
BTBenjamin Trzaskoma
Benjamin Trzaskoma
KRKarin Rosén
Karin Rosén
TMThomas Murphy
Thomas Murphy
Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep. We examined the effect of omalizumab on sleep-related outcomes during 3–6 months omalizumab or placebo treatment and a 16-week follow-up period within three Phase III double-blind randomized placebo-controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies using sleep-related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive. Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discontinuation, sleep quality worsened. Sleep scores demonstrated moderate-to-strong correlation between them, and the change in sleep scores was associated with changes in itch and hives. Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in sleep than those in other treatment arms. Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)

Verified
Closed access
AGAna M Giménez-Arnau
Ana M Giménez-Arnau
MMMarcus Maurer
Marcus Maurer
JCJesus De La Cuadra
Jesus De La Cuadra
HMHoward I Maibach
Howard I Maibach